Deng Dawei, Zhang Yuhan, Zhang Rongzhi, Yi Jing, Dong Jianli, Sha Liyan, Yan Meiqin
Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
Department of Nursing, School of Nursing, Shanxi Medical University, Taiyuan, Shanxi, China.
Arch Med Res. 2023 Feb;54(2):124-134. doi: 10.1016/j.arcmed.2022.12.012. Epub 2023 Feb 8.
Gastric cancer (GC) is often diagnosed at an advanced stage and thus patients have a poor prognosis. This implies that early detection of this cancer will improve patient prognosis and survival. This systematic review explored the association of circulating protein and metabolite biomarkers with GC development.
A literature search was conducted until November 2021 on Medline, Embase, Cochrane library, and Web of Science databases. Studies were included if they assessed circulating proteins and metabolites in blood, urine, or saliva and determined their association with GC risk. Quality of identified studies was determined using the Newcastle-Ottawa scale for cohort studies. Random and fixed effects meta-analyses were performed to calculate pooled odds ratio.
A total of 53 studies were included. High levels of anti-Helicobacter pylORi IgG levels, pepsinogen I (PGI) <30 µg/L and serum pepsinogen I/ pepsinogen II (PGI/II) ratio<3 were positively associated with risk of developing GC (pooled odds ratio (OR): 2.70; 95% CI: 1.44-5.04, 5.96, 95% CI: 2.65-13.42 and 4.43; 95% CI: 3.04-6.47). In addition, an inverse relationship was found between ferritin, iron and transferrin levels and risk of developing GC (OR: 0.62; 95% CI: 0.38-1,0.97; 95% CI: 0.94-1 and 0.85; 95% CI: 0.76-0.94). However, there was no association between levels of glucose, cholesterol, vitamin C, vitamin B12, vitamin A, α-Carotene, β-Carotene, α-Tocopherol, γ-Tocopherol, and GC risk.
The pooled analysis demonstrated that high levels of anti-Helicobacter pylORi IgG, PGI<30µg/L and serum PGI/II ratio <3 and low levels of ferritin, iron and transferrin were associated with risk of GC.
胃癌（GC）往往在晚期才被诊断出来，因此患者预后较差。这意味着早期发现这种癌症将改善患者的预后和生存率。本系统评价探讨了循环蛋白和代谢物生物标志物与胃癌发生之间的关联。
截至2021年11月，在Medline、Embase、Cochrane图书馆和Web of Science数据库中进行了文献检索。如果研究评估了血液、尿液或唾液中的循环蛋白和代谢物，并确定了它们与胃癌风险的关联，则纳入研究。使用纽卡斯尔-渥太华量表对队列研究进行确定已识别研究的质量。进行随机和固定效应荟萃分析以计算合并优势比。
共纳入53项研究。抗幽门螺杆菌IgG水平升高、胃蛋白酶原I（PGI）<30μg/L和血清胃蛋白酶原I/胃蛋白酶原II（PGI/II）比值<3与胃癌发生风险呈正相关（合并优势比（OR）：2.70；95%可信区间：1.44 - 5.04、5.96、95%可信区间：2.65 - 13.42和4.43；95%可信区间：3.04 - 6.47）。此外，发现铁蛋白、铁和转铁蛋白水平与胃癌发生风险呈负相关（OR：0.62；95%可信区间：0.38 - 1.097；95%可信区间：0.94 - 1和0.85；95%可信区间：0.76 - 0.94）。然而，葡萄糖、胆固醇、维生素C、维生素B12、维生素A、α-胡萝卜素、β-胡萝卜素、α-生育酚、γ-生育酚水平与胃癌风险之间没有关联。
汇总分析表明，抗幽门螺杆菌IgG水平升高、PGI<30μg/L和血清PGI/II比值<3以及铁蛋白、铁和转铁蛋白水平降低与胃癌风险相关。
